Search Within

Jose T Baselga

  1. "Sujata Patil"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (4)
Groups
  1. Biostatistics Service (18)
  2. Breast Medicine Service (18)
  3. Department of Medicine (18)
  4. Epidemiology and Biostatistics (18)
  5. Solid Tumor Oncology Division (18)
  6. Survivorship Research (18)

More Groups

People
  1. Clifford Hudis (18)
  2. Sujata Patil (18)
  3. Larry Norton (13)
  4. Chau Dang (12)
  5. Shanu Modi (11)
  6. Neil Iyengar (9)

More People

Years
  1. 2018 (1)
  2. 2017 (2)
  3. 2016 (6)
  4. 2015 (6)
  5. 2014 (3)
Publications
  1. Journal of Clinical Oncology (9)
  2. Cancer Research (6)
  3. Breast Cancer Research and Treatment (1)
  4. Clinical Breast Cancer (1)
  5. The Oncologist (1)
Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (6)
  3. Elsevier Inc. (1)
  4. Oxford University Press (1)
  5. Springer (1)

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer
    Meeting Abstract

    Wang, R.; Yu, A. F.; Steingart, R.; Patil, S.; Baselga, J.; Norton, L.; Hudis, C.; Dang, C. T.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience
    Journal Article

    Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
    The Oncologist (2017)

    Fulltext@MSK | Save
  • Pilot trial of an implantable microdevice for in vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy
    Meeting Abstract

    Traina, T. A.; Plitas, G.; Reis-Filho, J. S.; Morris, E. A.; Hughes, M.; Sung, J. S.; Patil, S.; Piscuoglio, S.; Park, S.; Greenberg, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution
    Meeting Abstract

    Argolo, D.; Friedman, M.; Smyth, L.; Iyengar, N.; Singh, J.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C.; Dang, C.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study
    Journal Article

    Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save
  • Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling
    Meeting Abstract

    Gucalp, A.; Proverbs-Singh, T. A.; Razavi, P.; Chandarlapaty, S.; Patil, S.; Ross, D. S.; Zehir, A.; Baselga, J.; Hudis, C. A.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save